Conclusion of a non-exclusive discount contract according to Section 130a (8) SGB V on drugs with the active ingredient everolimus (ATC code: L01EG02, patent-free oncological indication that is not related to TSC and L04AA18) within the period from 01.04.2022 to 31.03.2024 with the possibility of concluding the contract at any time during runtime (“open-house model”).

The contractual partners can be viewed at: https://www.aok-gesundheitpartner.de/nds/arzneimittel/rabatt/index_03504.html?bl=nds

AOK Niedersachsen offers the active substance everolimus (ATC code: L01EG02, patent-free oncological indication that is not related to TSC and L04AA18). The health insurance fund offers discount contracts to all interested pharmaceutical companies without selection decisions for the period until exclusive contracts come into force as a result of a formal award procedure in accordance with the regulations of the 4th part of the GWB. The contracts are concluded within the framework of an “open-house model” and act as a bridge between the start of generic competition (patent expiration) and the payment of exclusive contracts. The contracts offered are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform — individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months, the earliest start of the contract is April 1, 2022. All contracts end on 31.03.2024 at the latest, regardless of the date the respective contract was concluded. You can join or conclude a contract within the twenty-four month period on the first of each month. There is a right of termination six weeks to the end of the month. The AOK — The health insurance fund for Lower Saxony reserves the right to replace non-exclusive open-house discount contracts with exclusive discount contracts during the contract period. With the entry into force of advertised exclusive discount contracts, the open-house contracts are terminated in accordance with the contractual regulation, i.e. the open-house contracts end automatically. According to the experience of AOK Niedersachsen, exclusive discount contracts usually come into force six to eight months after the publication of the corresponding tender notice in the supplement to the Official Journal of the European Union. Future contract partners in the open-house model are asked to inform themselves regularly about these tender notices in the supplement to the Official Journal of the European Union.

Interested pharmaceutical companies can request the contractual documents and the contractual terms and conditions at the contact address given under I.1).

Contracts for the active substance everolimus (ATC code: L01EG02, patent-free oncological indication, not related to TSC and L04AA18) will be concluded for the first time with effect from April 1, 2022. Interested parties who wish to become contract partners by this date must submit the contract documents to be submitted to the address specified in the contract documents by 04.03.2022. It depends on access at AOK Niedersachsen. Later contracts can be concluded during the twenty-four-month maximum period on the first of each month. In terms of organization, a lead time of usually 35 calendar days is required by AOK in order to be able to guarantee the necessary work, such as contract notification in the Lauer Tax®. The exact deadlines for receipt will be announced with the contract documents. This publication is not the award of a public contract within the meaning of the Directive (2014/24/EU) or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used.